

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Canigen Bb Suspension for Injection in Pre-filled Syringe for Dogs

Date Created: December 2021

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Canigen Bb Suspension for Injection in Pre- filled Syringe for Dogs
Applicant	MSD Animal Health UK Limited
	Walton Manor
	Walton
	Milton Keynes
	Buckinghamshire
	MK7 7AJ
Active substance(s)	Bordetella bronchiseptica
ATC Vetcode	Q107AB03
Target species	Dogs
Indication for use	For active immunisation of dogs against Bordetella bronchiseptica to reduce clinical signs of upper respiratory tract disease and bacterial shedding post infection.
	Onset of immunity: 2 weeks.
	Duration of immunity: 7 months after primary vaccination and 1 year after re-vaccination.

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Informed Consent application in accordance with Article 13c of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	23/11/2021

I. SCIENTIFIC OVERVIEW

The quality / safety / efficacy aspects of this product are identical to Nobivac Respira Bb Suspension for Injection in Pre-filled Syringe for Dogs.

II. OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile of the product is favourable.

POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)